[Characteristics of Cardiotoxicity in Breast Cancer Treatment and the Importance of Onco-Cardiology].

Abstract

Cardiovascular disease and dysfunction in cancer patients is often a medical problem. Cancer therapeutics related cardiac dysfunction(CTRCD)has long been known as late toxicity of anthracycline use and irradiation of the preserved breast and chest wall in breast cancer patients, CTRCD has received increasing attention, but there is still little evidence for prevention or prediction. Breast cancer has a good treatment outcome, and there is a need to address late cardiotoxicity. In recent years, the introduction of new drugs has forced us to deal with patients with new cardiotoxic and cardiovascular complications, such as myocarditis, which, combined with the increase in the number of cancer survivors with improved outcomes, has increased the number of situations requiring the concurrent consultation of oncologists and cardiologists. The goal is to improve life outcomes with optimal cancer treatment while reducing cardiac disease through appropriately timed interventions. Since drugs play different roles in initial treatment aiming for cure and palliative drug therapy for metastatic or recurrent breast cancer, cardiotoxicity should be discussed separately in close communication with cardiologists when considering the risk-benefit ratio. Discussions regarding the continuation of cardiac treatment and cancer treatment need to be done separately in'close collaboration'between oncologists and cardiologists.